ʻO Prime Medicine, Inc., kahi hui i hoʻokumu e hoʻokō i ka hoʻohiki a Prime Editing, i kēia lā i hoʻolaha i ka hoʻohui o nā hiki i kāna paepae e pili ana i ka noiʻi ʻepekema hou.

"Ua hauʻoli nui mākou i ka ʻike ʻana i nā hoʻomaikaʻi hou aʻe e hoʻonui hou ai i ka hiki ʻana o Prime Editing ma ke ʻano he lāʻau lapaʻau," i ʻōlelo ʻia ʻo Keith Gottesdiener, MD, CEO o Kuhina Nui Medicine. "ʻO kēia mau holomua, ma luna o kahi ʻenehana hoʻokumu kahua paʻa mua, e hoʻonui paha i ka pono o Prime Editing, a e hoʻonui i nā wahi e hana ai ʻo Prime Editing, e hoʻonui ana i kā mākou hiki i nā maʻi hou aʻe i hiki ʻole i kahi hoʻoponopono hoʻoponopono ʻē aʻe ke hiki. e kamaʻilio. ”

Me kēia mau holomua hou i hana ʻia e nā ʻepekema kūwaho, a me nā hana hoʻomau a Prime Medicine e kāna hui hoʻomohala kūloko, ke manaʻo nei ka ʻoihana e hoʻonui hou aʻe i ka maʻalahi o ka Prime Editing, pololei, a me ka maikaʻi. Hiki i nā mākau i wehewehe ʻia i loko o nā pepa i hala iho nei ma ka Nature Biotechnology a me ka Cell ke hiki ke hoʻomohala i nā therapeutics ʻoi aku ka maikaʻi ma o ka hoʻomaikaʻi ʻana i nā hana ʻē aʻe.

Hoʻokahi o ka mua e pili ana i kahi alakaʻi maikaʻi ʻo Prime Editing RNA (pegRNA). Hoʻohana ka Prime Editing i kahi moleola pegRNA e ʻike ai i ka ʻenekini a me ke kuhikuhi ʻana i ka hoʻoponopono a makemake ʻia paha e hoʻoponopono ai. I loko o kahi pepa i paʻi ʻia ma Nature Biotechnology ma ʻOkakopa 4, 2021, nā mea kākau i alakaʻi ʻia e David R. Liu, kekahi o nā mea i hoʻokumu i ka Prime Medicine, i hōʻike ʻia e hiki i ka optimized, engineered pegRNAs (epegRNAs) ke hoʻomaikaʻi i ka pono o ka hoʻoponopono i nā manawa he nui.

Ke alualu pū nei ka ʻoihana i nā hoʻolālā no ka hoʻomaikaʻi ʻana i ka pono ma o ka modulate ʻana i kahi ala hoʻoponopono DNA kikoʻī. I kahi pepa i paʻi ʻia ma Cell ma ʻOkakopa 14, 2021, nā mea kākau i alakaʻi ʻia e Liu lāua ʻo Britt Adamson i hoʻomaopopo i kahi ala hoʻomaikaʻi DNA kikoʻī, i kapa ʻia ʻo ke ala hoʻoponopono kūlike ʻole, e hoʻonui pono ai i ka pono nui o ka hoʻoponopono ʻana. Ua hōʻike lākou hiki ke hoʻonui ʻia ka hana hoʻoponopono ʻana i mau manawa he nui, a hiki i nā huahana ke makemake ʻole ʻia ke hoʻoliʻiliʻi i nā pā he nui, e ke hoʻololi ʻana i ke ala hoʻoponopono kūlike ʻole ma o nā ʻano he nui.

Mālama ʻo Prime Medicine i nā kuleana kalepa mai ka Broad Institute of MIT a me Harvard e hoʻohana i ka Prime Editing no nā hana hoʻoponopono kanaka, ʻoiai nā ʻepekema a me nā hui a puni ka honua e hoʻohana nei i ka Prime Editing no nā hana noiʻi a me nā noi ʻē aʻe.

He aha e lawe ʻia mai kēia ʻatikala:

“These advancements, on top of an already groundbreaking foundational technology, are likely to increase the efficiency of Prime Editing, and will broaden the areas where Prime Editing might work, potentially extending our reach to additional diseases that no gene editing approach has yet been able to address.
Mālama ʻo Prime Medicine i nā kuleana kalepa mai ka Broad Institute of MIT a me Harvard e hoʻohana i ka Prime Editing no nā hana hoʻoponopono kanaka, ʻoiai nā ʻepekema a me nā hui a puni ka honua e hoʻohana nei i ka Prime Editing no nā hana noiʻi a me nā noi ʻē aʻe.
Prime Editing uses a pegRNA molecule to find the gene target and to direct the desired repair or edit.